Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 113,451 shares of the company’s stock, valued at approximately $3,922,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. owned approximately 0.13% of IDEAYA Biosciences at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of IDYA. Farther Finance Advisors LLC grew its holdings in shares of IDEAYA Biosciences by 171.1% during the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after purchasing an additional 580 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of IDEAYA Biosciences in the third quarter valued at about $38,000. ANTIPODES PARTNERS Ltd lifted its position in IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after buying an additional 380 shares in the last quarter. Abich Financial Wealth Management LLC bought a new stake in IDEAYA Biosciences during the 3rd quarter worth about $58,000. Finally, Daiwa Securities Group Inc. grew its holdings in IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after acquiring an additional 436 shares during the last quarter. Institutional investors own 98.29% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research note on Wednesday, February 18th. Wells Fargo & Company raised their price target on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, April 14th. Guggenheim boosted their price objective on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. The Goldman Sachs Group upped their price objective on IDEAYA Biosciences from $31.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, April 14th. Finally, Wedbush increased their price objective on IDEAYA Biosciences from $52.00 to $58.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Fifteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.69.
IDEAYA Biosciences Price Performance
Shares of NASDAQ:IDYA opened at $29.65 on Thursday. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of -18.53 and a beta of -0.04. The company has a 50 day moving average of $31.15 and a 200-day moving average of $32.83. IDEAYA Biosciences, Inc. has a one year low of $18.25 and a one year high of $39.28.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. During the same quarter in the prior year, the company earned ($0.82) EPS. IDEAYA Biosciences’s revenue for the quarter was down 39.4% compared to the same quarter last year. Equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -4.28 earnings per share for the current year.
Insider Activity at IDEAYA Biosciences
In related news, Director Jeffrey Stein purchased 50,000 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were bought at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the purchase, the director directly owned 54,281 shares in the company, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.70% of the company’s stock.
IDEAYA Biosciences Company Profile
IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.
Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.
Featured Articles
- Five stocks we like better than IDEAYA Biosciences
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
